You are here

  • Home
  • Archive
  • Volume 26, Issue 9
  • Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial

Citation Tools

Article menu
Download PDFPDF
Ovarian Cancer
Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Herzog TJ, Kutarska E, Bidzińsk M, et al
Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial
International Journal of Gynecologic Cancer 2016;26:1580-1585.